Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYBRID: HFSRS vs WBRT with EGFR-TKI in NSCLC Brain Metastases
NCT02882984Phase 3Unknown
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Mar 2015
- Primary completion
- Mar 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib, erlotinib, icotinib in non-small cell lung cancer (NSCLC), brain metastases, sponsored by Sichuan Provincial People's Hospital. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT02882984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882984.